. 2014 Oct 15;9(10):e85556. doi: 10.1371/journal.pone.0085556

Table 1. Study characteristics.

Reference	Country	Study design	age	Exposure pathway	biomarker	Biologic specimen	Cases/controls	OR or RR (95%CI)
Arrebola2013	Spain	Cross-sectional	16-	Background	p,p′-DDE	Serum lipid	34/352	1.69(0.54–5.22)^a
Wu2012	USA	Prospective	30–55	Nurses	PCB-153	Serum lipid	10/214	2.19(0.72–6.68)^a
			30–55	Nurses	PCB-153	Serum lipid	6/135	0.76(0.22–2.60)^a
			30–55	Nurses	PCBs	Serum lipid	9/215	1.30(0.43–3.93)^a
			30–55	Nurses	PCBs	Serum lipid	7/134	0.79(0.23–2.71)^a
			30–55	Nurses	p,p′-DDE	Serum lipid	9/215	1.32(0.41–4.27)^a
			30–55	Nurses	p,p′-DDE	Serum lipid	10/131	1.79(0.54–5.86)^a
Persky2012	USA	Cross-sectional	35-	Electrical utilities company men	PCB-153	Serum lipid	7/56	3.1(1.2–7.8)^a
			35-	Electrical utilities company men	PCBs	Serum lipid	7/56	3.0(1.3–7.2)^a
Gasull2012	Spain	Cross-sectional	18–74	Background	PCB-153	Serum	77/192	1.6(1.2–2.4)^a
			18–74	Background	PCBs	Serum	77/193	1.7(1.1–2.6)^a
			18–74	Background	p,p′-DDE	Serum	73/207	1.1(0.7–1.7)^a
Silverstone2012	USA	Cross-sectional	18-	PCBs plant area	PCBs	Serum	78/157	2.78(1.00–7.73)
			18–55	PCBs plant area	PCBs	Serum	27/111	4.78(1.11–20.6)
			55-	PCBs plant area	PCBs	Serum	51/47	4.19(0.26–68.12)
Lee 2011	Sweden	Prospective	70	background	PCB-153	Serum	12/277	1.7(0.5–6.2)
			70	background	p,p′-DDE	Serum	16/271	2.1(0.7–6.3)
Airaksinen2011	Finland	Cross-sectional	70	background	PCB-153	Serum lipid	69/398	1.64(0.92–2.93)^b
			70	background	PCB-153	Serum lipid	10/121	1.03(0.25–4.18)^b
			70	background	PCB-153	Serum lipid	23/184	1.97(0.75–5.23)^b
			70	background	PCB-153	Serum lipid	36/93	2.3(0.87–6.11)^b
			70	background	p,p′-DDE	Serum lipid	62/398	1.75(0.96–3.19)^b
			70	background	p,p′-DDE	Serum lipid	7/120	0.88(0.18–4.35)^b
			70	background	p,p′-DDE	Serum lipid	18/175	1.91(0.69–5.27)^b
			70	background	p,p′-DDE	Serum lipid	37/103	1.82(0.71–4.65)^b
Tanaka 2011	Japan	Cross-sectional	40–64	background	PCB-153	Serum	32/85	0.95(0.90–1.00)^a
			40–64	background	PCB-153	Serum lipid	32/85	0.73(0.51–1.07)
Grandjean2011	Faroe Islands	Cross-sectional	70–74	Aquatic product	PCBs	Serum lipid	168/544	1.11(0.91–1.35)^a
			70–74	Aquatic product	p,p′-DDE	Serum lipid	168/544	1.01(0.87–1.16)^a
Son2010	Korea	Cross-sectional	40-	Background	p,p′-DDE	Serum	27/26	26.6(2.0–349.1)
			40-	Background	p,p′-DDE	Serum lipid	28/26	12.7(1.9–83.7)
Everett2010	USA	Cross-sectional	20-	Background	p,p′-DDE	Serum lipid	334/2715	1.08(0.58–2.03)^a
Ukropec2010	Slovakia	Cross-sectional	21–75	Heavy pollution	PCBs	Serum lipid	120/699	1.86(1.09–3.17)
			21–75	Heavy pollution	p,p′-DDE	Serum lipid	125/694	1.94(1.11–3.78)
Lee2010	USA	Perspective	18–30	Background	PCB-153	Serum lipid	39/45	0.8(0.2–2.6)^a
			18–30	Background	p,p′-DDE	Serum lipid	47/45	0.7(0.2–1.9)^a
Philibert2009	Canada	Cross-sectional	15–86	Aquatic product	PCB-153	Serum	25/101	4.91(1.27–19.01)
			15–86	Aquatic product	PCB-153	Serum lipid	25/101	6.46(2.07–36.63)
			15–86	Aquatic product	PCBs	Serum	25/101	4.91(1.27–19.01)
			15–86	Aquatic product	PCBs	Serum lipid	25/101	5.51(1.26–24.07)
			15–86	Aquatic product	p,p′-DDE	Serum	25/101	6.11(1.37–27.3)
			15–86	Aquatic product	p,p′-DDE	Serum lipid	25/101	3.56(0.97–13.08)
Rignell-Hydbom2009	Sweden	Prospective	50–59	Background women	PCB-153	Serum	371/371	0.99(0.71–1.4)^c
			50–59	Background women	PCB-153	Serum	208/208	0.91(0.59–1.4)^c
			50–59	Background women	PCB-153	Serum	163/163	1.1(0.66–1.9)^c
			50–59	Background women	PCB-153	Serum	107/107	1.4(0.72–2.6)^c
			50–59	Background women	PCB-153	Serum	74/74	1.4(0.67–3.1)^c
			50–59	Background women	PCB-153	Serum	39/39	1.6(0.61–4.0)^c
			50–59	Background women	p,p′-DDE	Serum	371/371	1.1(0.76–1.5)^c
			50–59	Background women	p,p′-DDE	Serum	208/208	0.9(0.57–1.4)^c
			50–59	Background women	p,p′-DDE	Serum	163/163	1.3(0.78–2.2)^c
			50–59	Background women	p,p′-DDE	Serum	107/107	1.5(0.8–2.8)^c
			50–59	Background women	p,p′-DDE	Serum	74/74	2.5(0.97–6.4)^c
			50–59	Background women	p,p′-DDE	Serum	39/39	5.5(1.2–25)^c
Turyk2009	USA	Prospective	25–76	Aquatic product	p,p′-DDE	Serum	24/285	7.1(1.6–31.9)
			25–76	Aquatic product	PCBs	Serum	21/293	1.8(0.6–5.0)
Wang2008	Taiwan, China	Cross-sectional	30-	Rice-bran oil men	PCBs	Serum	155/152	1.7(0.7–4.6)^a
			30-	Rice-bran oil women	PCBs	Serum	233/218	5.5(2.3–13.4)^a
Codru2007	USA	Cross-sectional	30-	Background	PCBs	Serum		2.8 (0.7–10.8)^a
			30-	Background	PCBs	Serum lipid		2.6 (0.8–8.1)^a
			30-	Background	PCB-153	Serum		3.0 (0.7–12.8)^a
			30-	Background	PCB-153	Serum lipid		1.4 (0.4–4.8)^a
			30-	Background	p,p′-DDE	Serum		2.6 (0.8–8.8)^a
			30-	Background	p,p′-DDE	Serum lipid		2.4 (0.7–8.3)^a
Rignell-Hydbom2007	Sweden	Cross-sectional	29–59	Aquatic product women	PCB-153	Serum lipid	15/528	1.4(0.8–2.5)^a
			29–59	Aquatic product women	p,p′-DDE	Serum lipid	15/528	1.3(1.1–1.5)^a
Cox2007	USA	Cross-sectional	20–74	Background	p,p′-DDE	Serum	45/768	2.63(1.2–5.8)^a
			20–74	Background	p,p′-DDE	Serum lipid	35/560	1.5(0.8–2.9)^a
Lee2006	USA	Cross-sectional	12-	Background	PCB-153	Serum lipid	52/598	6.8(3.0–15.5)
			12-	Background	p,p′-DDE	Serum lipid	69/704	4.3(1.8–10.2)
Rylander2005	Sweden	Cross-sectional	49–84	Aquatic product	PCB-153	Serum lipid	22/358	1.16(1.03–1.32)
			49–84	Aquatic product	p,p′-DDE	Serum lipid	22/358	1.05(1.01–1.09)
Fierens2003	Belgium	Case-control	50.3–59.4	Background	PCBs	Serum lipid	9/248	7.6(1.58–36.3)

Different models adjusted by confounding, such as sex, age, BMI, total cholesterol and triglycerides, and various compounds.

stratified by BMI.

stratified by the years diagnosed after the baseline investigation.